Atorvastatin

Generic Name: Atorvastatin

Brand Names: Atorvaliq, Caduet, Lipitor, Lypqozet

Drug Type: Small Molecule

Chemical Formula: C_₃₃H_₃₅FN_₂O_₅

CAS Number: 134523-00-5

Unique Ingredient Identifier: A0JWA85V8F

Background: Atorvastatin (Lipitor®), is a lipid-lowering drug included in the statin class of medications. By inhibiting the endogenous production of cholesterol in the liver, statins lower abnormal cholesterol and lipid levels, and ultimately reduce the risk of cardiovascular disease. More specifically, statin medications competitively inhibit the enzyme hydroxymethylg...

Indication: Atorvastatin is indicated for the treatment of several types of dyslipidemias, including primary hyperlipidemia and mixed dyslipidemia in adults, hypertriglyceridemia, primary dysbetalipoproteinemia, homozygous familial hypercholesterolemia, and heterozygous familial hypercholesterolemia in adolescent patients with failed dietary modifications.
...

Associated Conditions: Anginal Pain, Cardiovascular Complications, Cardiovascular Disease (CVD), Coronary Artery Disease (CAD), Coronary artery thrombosis, Dysbetalipoproteinemia, Fredrickson Type III lipidemia, Heterozygous Familial Hypercholesterolemia (HeFH), High Cholesterol, Homozygous Familial Hypercholesterolaemia (HoFH), Hospitalizations, Hypertension, Essential Hypertension, Hypertriglyceridemias, Mixed Dyslipidemias, Mixed Hyperlipidemia, Myocardial Infarction, Non-familial hypercholesterolemia, Nonfatal Myocardial Infarction, Postoperative Thromboembolism, Primary Hypercholesterolemia, Stroke, Thrombosis, Transient Ischemic Attack, Elevation of serum triglyceride levels, Heterozygous familial hyperlipidemia, Non-familial hyperlipidemia, Primary Hyperlipidemia, Revascularization procedures

Associated Therapies: -

Clinical Trials

A Coronary IVUS Study to Compare Torcetrapib/Atorvastatin to Atorvastatin Alone in Subjects With Coronary Heart Disease

Phase 3

Completed

Conditions: Coronary Disease
Hyperlipidemia
Coronary Arteriosclerosis

First Posted Date: 2005-08-24

Last Posted Date: 2007-12-10

Lead Sponsor: Pfizer

Target Recruit Count: 1100

Registration Number: NCT00134173

Locations: 🇪🇸
Pfizer Investigational Site, Madrid, Spain

A Study Comparing The Efficacy & Safety Of Torcetrapib/Atorvastatin And Atorvastatin In Subjects With High Triglycerides

Phase 3

Completed

Conditions: Hypertriglyceridemia
Hyperlipoproteinemia Type IV

First Posted Date: 2005-08-24

Last Posted Date: 2007-11-16

Lead Sponsor: Pfizer

Target Recruit Count: 160

Registration Number: NCT00134498

Locations: 🇨🇦
Pfizer Investigational Site, Ste-Foy, Quebec, Canada

Study To Evaluate The Safety And Efficacy Of Torcetrapib/Atorvastatin In Subjects With Familial Hypercholerolemia

Phase 3

Completed

Conditions: Hypercholesterolemia, Familial
Hyperlipidemia

First Posted Date: 2005-08-24

Last Posted Date: 2007-10-30

Lead Sponsor: Pfizer

Target Recruit Count: 400

Registration Number: NCT00134485

Locations: Pfizer Investigational Site

A Study in People With High Cholesterol

Phase 2

Completed

Conditions: Hypercholesterolemia

First Posted Date: 2005-08-23

Last Posted Date: 2007-04-06

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 300

Registration Number: NCT00133380

Locations: 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kingsport, Tennessee, United States